Understanding the role of SORL1 in Alzheimer's disease
Official title: Molecular analysis of SORL1 function and dysfunction in Alzheimer's disease
Funded at Emory University · NIH-10825622 · Data updated 2026-11-12
This study is looking at how a protein called SORL1 might play a role in the development of Alzheimer's disease, with the hope that understanding this could lead to new treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $234,750 |
| NIH project number | 5R21AG082333-02 |
| Project ID | NIH-10825622 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those diagnosed with late-onset Alzheimer's.
✕Less likely to help
Patients with early-onset Alzheimer's disease unrelated to SORL1 mutations may not benefit from this research.
What this research studies
This research investigates how the SORL1 protein affects the development and progression of Alzheimer's disease (AD). By analyzing the molecular mechanisms of SORL1, the study aims to uncover how disruptions in protein trafficking contribute to neurodegeneration in AD. Patients may benefit from insights gained into the genetic factors and pathways involved in AD, potentially leading to new therapeutic strategies. The research employs advanced molecular biology techniques to explore the relationship between SORL1 mutations and AD pathology.
Why it matters
Potential benefit: If successful, this research could lead to new interventions that target the underlying mechanisms of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic factors in Alzheimer's disease, making this approach a continuation of established findings.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Li, Lian — Emory University
- Study coordinator: Li, Lian
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.